JPH0114230B2 - - Google Patents
Info
- Publication number
- JPH0114230B2 JPH0114230B2 JP1054681A JP1054681A JPH0114230B2 JP H0114230 B2 JPH0114230 B2 JP H0114230B2 JP 1054681 A JP1054681 A JP 1054681A JP 1054681 A JP1054681 A JP 1054681A JP H0114230 B2 JPH0114230 B2 JP H0114230B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- water
- add
- reaction
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 claims description 33
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 23
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 150000003548 thiazolidines Chemical class 0.000 claims description 6
- 238000006460 hydrolysis reaction Methods 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- -1 methylenedioxy group Chemical group 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000013078 crystal Substances 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 239000002253 acid Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 7
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 238000001035 drying Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- BYYLQWYSRDRNLN-UHFFFAOYSA-N 3-ethoxy-4-pentoxybenzaldehyde Chemical compound CCCCCOC1=CC=C(C=O)C=C1OCC BYYLQWYSRDRNLN-UHFFFAOYSA-N 0.000 description 3
- 102000016912 Aldehyde Reductase Human genes 0.000 description 3
- 108010053754 Aldehyde reductase Proteins 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- CRPGRUONUFDYBG-UHFFFAOYSA-N risarestat Chemical compound C1=C(OCC)C(OCCCCC)=CC=C1C1C(=O)NC(=O)S1 CRPGRUONUFDYBG-UHFFFAOYSA-N 0.000 description 3
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- YGKYDDVADBQGTF-UHFFFAOYSA-N 2-(3-ethoxy-4-pentoxyphenyl)-2-hydroxyacetonitrile Chemical compound CCCCCOC1=CC=C(C(O)C#N)C=C1OCC YGKYDDVADBQGTF-UHFFFAOYSA-N 0.000 description 2
- XIEYWJBKLFCZSX-UHFFFAOYSA-N 2-chloro-2-(3,4-diethoxyphenyl)acetonitrile Chemical compound CCOC1=CC=C(C(Cl)C#N)C=C1OCC XIEYWJBKLFCZSX-UHFFFAOYSA-N 0.000 description 2
- 206010007749 Cataract diabetic Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000007025 diabetic cataract Diseases 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- CWUBOATXSCLVPQ-UHFFFAOYSA-N 2-(3,4-diethoxyphenyl)-2-hydroxyacetonitrile Chemical compound CCOC1=CC=C(C(O)C#N)C=C1OCC CWUBOATXSCLVPQ-UHFFFAOYSA-N 0.000 description 1
- FYDGWCYXUPKUPP-UHFFFAOYSA-N 2-chloro-2-(3-ethoxy-4-pentoxyphenyl)acetonitrile Chemical compound CCCCCOC1=CC=C(C(Cl)C#N)C=C1OCC FYDGWCYXUPKUPP-UHFFFAOYSA-N 0.000 description 1
- SSTRYEXQYQGGAS-UHFFFAOYSA-N 3,4-diethoxybenzaldehyde Chemical compound CCOC1=CC=C(C=O)C=C1OCC SSTRYEXQYQGGAS-UHFFFAOYSA-N 0.000 description 1
- DSQUWKACUXHOOX-UHFFFAOYSA-N 5-(3,4-diethoxyphenyl)-1,3-thiazolidine-2,4-dione Chemical compound C1=C(OCC)C(OCC)=CC=C1C1C(=O)NC(=O)S1 DSQUWKACUXHOOX-UHFFFAOYSA-N 0.000 description 1
- ZARIWPKPVKTVCD-UHFFFAOYSA-N 5-(3-ethoxy-4-pentoxyphenyl)-1,3-thiazolidine Chemical compound C(C)OC=1C=C(C=CC1OCCCCC)C1CNCS1 ZARIWPKPVKTVCD-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical group 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- 125000003935 n-pentoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 230000018791 negative regulation of catalytic activity Effects 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1054681A JPS57123175A (en) | 1981-01-26 | 1981-01-26 | Preparation of thiazolidine derivative |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1054681A JPS57123175A (en) | 1981-01-26 | 1981-01-26 | Preparation of thiazolidine derivative |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS57123175A JPS57123175A (en) | 1982-07-31 |
JPH0114230B2 true JPH0114230B2 (no) | 1989-03-10 |
Family
ID=11753251
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP1054681A Granted JPS57123175A (en) | 1981-01-26 | 1981-01-26 | Preparation of thiazolidine derivative |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS57123175A (no) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3479419D1 (en) * | 1983-01-17 | 1989-09-21 | Pfizer | Aldose reductase inhibiting 5-(2-alkoxyphenyl)thiazolidinediones |
US20070049593A1 (en) | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
US7659263B2 (en) | 2004-11-12 | 2010-02-09 | Japan Tobacco Inc. | Thienopyrrole compound and use thereof as HCV polymerase inhibitor |
-
1981
- 1981-01-26 JP JP1054681A patent/JPS57123175A/ja active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS57123175A (en) | 1982-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1263395A (en) | ¬5-(4-chroman-2-ylalkoxy)benzyl|-thiazolidine compounds | |
KR920002131B1 (ko) | 타아졸리딘디온 유도체의 제조방법 | |
JPH06779B2 (ja) | チアゾリジオン誘導体およびそれを含んでなる医薬組成物 | |
JPS6242903B2 (no) | ||
JPS6332793B2 (no) | ||
EP0030861B1 (en) | Isoquinoline acetic acids and pharmaceutical compositions thereof | |
US4617312A (en) | Aldose reductase inhibiting 5-(2-alkoxyphenyl) thiazolidinediones | |
JPH1045733A (ja) | 2−(4−アルコキシ−3−シアノフェニル)チアゾール誘導体の製造法 | |
EP0033617A2 (en) | Thiazolidine derivatives and their production and medicinal compositions containing them | |
NO173938B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrido-pyridazinon-eddiksyrer | |
CZ279917B6 (cs) | Thiazolidinové sloučeniny obsahující chinonovou skupinu, způsob výroby a farmaceutické prostředky s jejich obsahem | |
US4587256A (en) | Novel thiazolidine derivatives | |
JPH0114230B2 (no) | ||
JPH044312B2 (no) | ||
CA1140928A (en) | Aldose reductase inhibiting quinolylhydantions | |
JPS61502959A (ja) | 4↓−(イソキサゾリル)↓−チアゾ−ル↓−2↓−オキサミド酸誘導体 | |
KR860001581B1 (ko) | 스피로-3-헤테로-아졸론의 제조방법 | |
KR870001267B1 (ko) | 5-(2-알콕시페닐)티아졸 리딘디온의 제조방법 | |
US4906757A (en) | Process for the preparation of dextrorotatory 3-(3-pyridyl)-1H,3H-pyrrolo [1,2-c]-7-thiazolecarboxylic acid | |
US4457939A (en) | Aldose reductase inhibiting 5-(2-alkoxy-3-substituted phenyl)hydantoins | |
JPH0816059B2 (ja) | 免疫調節剤 | |
JPH0118905B2 (no) | ||
EP0112620B1 (en) | 5-(substituted phenyl) hydantoins | |
JP7198968B2 (ja) | チエノ[2,3-c]ピリダジン-4(1H)-オン系化合物の結晶形及びその製造方法並びに使用 | |
JPH04270273A (ja) | チアゾリジン−2,4−ジオン誘導体とその塩及びその製造法 |